Literature DB >> 30869654

Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.

Angela C Boroughs1,2, Rebecca C Larson1,2, Bryan D Choi1,3, Amanda A Bouffard1, Lauren S Riley1, Erik Schiferle4, Anupriya S Kulkarni5, Curtis L Cetrulo6, David Ting5,7,8, Bruce R Blazar9, Shadmehr Demehri4,5,8, Marcela V Maus1,5,7,8.   

Abstract

Regulatory T cells (Tregs) are key modulators of inflammation and are important for the maintenance of peripheral tolerance. Adoptive immunotherapy with polyclonal Tregs holds promise in organ transplantation, graft-versus-host disease, and autoimmune diseases, but may be enhanced by antigen-specific, long-lived Treg cells. We modified primary human Tregs with chimeric antigen-receptors (CARs) bearing different costimulatory domains and performed in vitro analyses of their phenotype and function. While neither the presence of a CAR nor the type of costimulation domain influenced Foxp3 expression in Tregs, the costimulation domain of the CARs affected CAR Treg surface phenotype and functions such as cytokine production. Furthermore, signaling from the CD28 costimulation domain maintained CAR Treg suppressor function, whereas 4-1B costimulation did not. In vivo, CAR Tregs accumulated at sites expressing target antigen, and suppressed antigen specific effector T cell responses; however, only CAR Tregs with CD28 signaling domains were potent inhibitors of effector T cell mediated graft rejection in vivo. Our findings support the use of CD28 based CAR-Tregs for tissue specific immune suppression in the clinic.

Entities:  

Keywords:  Autoimmunity; Costimulation; Immunology; Immunotherapy; T cells

Mesh:

Substances:

Year:  2019        PMID: 30869654      PMCID: PMC6538349          DOI: 10.1172/jci.insight.126194

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  62 in total

1.  Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Erin E Donovan; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

2.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Authors:  B Salomon; D J Lenschow; L Rhee; N Ashourian; B Singh; A Sharpe; J A Bluestone
Journal:  Immunity       Date:  2000-04       Impact factor: 31.745

4.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

Authors:  David L Porter; Bruce L Levine; Nancy Bunin; Edward A Stadtmauer; Selina M Luger; Steven Goldstein; Alison Loren; Julie Phillips; Sunita Nasta; Alexander Perl; Steven Schuster; Donald Tsai; Ambika Sohal; Elizabeth Veloso; Stephen Emerson; Carl H June
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

5.  Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism.

Authors:  David C Gondek; Li-Fan Lu; Sergio A Quezada; Shimon Sakaguchi; Randolph J Noelle
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

Review 6.  Tolerance, not immunity, crucially depends on IL-2.

Authors:  Thomas R Malek; Allison L Bayer
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

7.  Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis.

Authors:  Adam P Kohm; Pamela A Carpentier; Holly A Anger; Stephen D Miller
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

8.  4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.

Authors:  Beom K Choi; Jun S Bae; Eun M Choi; Woo J Kang; Shimon Sakaguchi; Dass S Vinay; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2003-12-23       Impact factor: 4.962

9.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

10.  CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Authors:  José L Cohen; Aurélie Trenado; Douglas Vasey; David Klatzmann; Benoît L Salomon
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  41 in total

1.  CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.

Authors:  Yuki Imura; Makoto Ando; Taisuke Kondo; Minako Ito; Akihiko Yoshimura
Journal:  JCI Insight       Date:  2020-07-23

2.  Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor.

Authors:  Ilian A Radichev; Jeongheon Yoon; David W Scott; Kurt Griffin; Alexei Y Savinov
Journal:  Cell Immunol       Date:  2020-09-30       Impact factor: 4.868

Review 3.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

4.  A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.

Authors:  Angela C Boroughs; Rebecca C Larson; Nemanja D Marjanovic; Kirk Gosik; Ana P Castano; Caroline B M Porter; Selena J Lorrey; Orr Ashenberg; Livnat Jerby; Matan Hofree; Gabriela Smith-Rosario; Robert Morris; Joshua Gould; Lauren S Riley; Trisha R Berger; Samantha J Riesenfeld; Orit Rozenblatt-Rosen; Bryan D Choi; Aviv Regev; Marcela V Maus
Journal:  Mol Ther       Date:  2020-07-25       Impact factor: 11.454

Review 5.  Targeting Stem Cell-Derived Tissue-Associated Regulatory T Cells for Type 1 Diabetes Immunotherapy.

Authors:  Mohammad Haque; Jugal Kishore Das; Xiaofang Xiong; Jianxun Song
Journal:  Curr Diab Rep       Date:  2019-08-30       Impact factor: 4.810

6.  CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice.

Authors:  Richard Y Fu; Alex C Chen; Meghan J Lyle; Chun-Yu Chen; Chao Lien Liu; Carol H Miao
Journal:  Cell Immunol       Date:  2020-09-16       Impact factor: 4.868

7.  In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes.

Authors:  Shiwani Agarwal; Julia D S Hanauer; Annika M Frank; Vanessa Riechert; Frederic B Thalheimer; Christian J Buchholz
Journal:  Mol Ther       Date:  2020-05-16       Impact factor: 11.454

Review 8.  Gene editing for immune cell therapies.

Authors:  Stefanie R Bailey; Marcela V Maus
Journal:  Nat Biotechnol       Date:  2019-06-03       Impact factor: 54.908

Review 9.  The Emerging Landscape of Immune Cell Therapies.

Authors:  Evan W Weber; Marcela V Maus; Crystal L Mackall
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

10.  CAR-Tregs as a Strategy for Inducing Graft Tolerance.

Authors:  Johanna C Wagner; Qizhi Tang
Journal:  Curr Transplant Rep       Date:  2020-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.